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PRINCIPLES AND PRACTICE
MODERN MANAGEMENT OF DUODENAL ULCER 
Alan Boyd B.Sc.
Introduction. Chronic peptic ulcer of the
duodenum is a common disease. It causes the loss 
of over two million working days per annum in 
the U.K. In Scotland, its sufferers occupy over 
one hundred thousand bed days, and, along with 
benign gastic ulcer it kills almost four hundred 
Scots per year.1,2' By the age of fifty about ten 
per cent of the male Scottish population will have 
been affected by it.
If it is not rare, neither is it new. The term 
peptic ulcer was first used in 1882 by Quincke, 
believing that pepsin was the prime culprit. Bilroth 
first performed his operation in 1881, so we have 
nearly a century of operative experience to draw 
from.
Yet despite this, there is still controversy over 
how this condition should be managed. Until 
recently our drug therapy was ineffective in 
altering the natural history of the disease, and even 
now has little place in recurrent ulceration. And 
trying to untangle the mass of surgical literature 
with many surgeons each promoting the virtues of 
one of the various manoeuvres, with at least nine 
major and a multitude of minor variants on offer, 
is not easy.
And why should this be? Largely because we 
still do not fully understand its multi-factorial 
aetiology, when applied to the individual. Many 
factors have been implicated, most now well 
founded, but some still a little dubiously, but we 
are still not in a position to relate these to each 
patient, and treat his disease specifically, even if 
we had the means. And on the surgical side the 
differing emphasis placed on the balance between 
effectiveness and sequelae, both morbid and 
mortal, compounded by the natural variations 
between surgeons' techniques and abilities, as 
well as patient variables have served to muddy 
the waters for those seeking clear cut answers.
However, in the last few years new develop­
ments have arisen, both in the medical and surgical 
managements which promise to radically improve 
the outlook for our patients. The advent of 
Histamine H2 receptor antagonists has given us a 
potent and specific means of reducing acid 
secretion, and the development of Highly Selective 
Vagotomy offers a less ablative approach with a 
marked reduction in the side effects so long 
associated with gastric surgery, and it is on these 
that I shall concentrate.
Uncomplicated Chronic Duodenal Ulcer
Conventional wisdom has it that the initial 
management of duodenal ulcer, in the absence of 
life threatening complications, should be con­
servative in all cases, and nothing has appeared in 
recent years to change this.
Admission to hospital is preferable, as bed rest 
still remains a corner stone of therapy and the 
release from domestic tensions and pressures may 
aid this. This alone is enough to bring relief of 
symptoms within a few days to many patients, 
a fact which must be borne in mind when assessing 
the efficiency of drugs. Eighty per cent of patients 
will remit symptomatically for a greater or lesser 
period without specific treatment.
Stopping smoking has been proven to speed 
healing of gastric ulcers, but the evidence in 
duodenal ulcer is less conclusive. Empirically, 
however it seems sensible and is retained by most 
clinicians.
A s  for diets, the milk-fish diet of the past has 
been discredited, with hourly milk feeding having 
shown to increase acid secretion, and no evidence 
of increased healing being found. Dietary advice 
should now be limited to avoiding those foods and 
alcohol which aggravate symptoms and to taking 
regular smallish meals.3
16
Drug treatment has evolved considerably in 
recent years, and there is now much evidence that 
healing can be accelerated as well as symptoms 
alleviated. The drugs available fall into five 
categories according to site of action.
1. Antacids. Providing purely symptomatic relief, 
these were the main stay of treatment until the 
newer drugs arrived.They remain useful adjuvant 
therapy for relief of symptoms, and should be 
allowed freely.
Total titration of gastric acidity is neither 
practical4 nor necessary. What is required is 
rapidity plus freedom from side effects, which is 
best achieved by balancing the cathartic and 
constipating effects of magnesium and aluminium 
compounds.
2. Anticholinergics. These are many and various 
yet differ little in their effects or side-effects. They 
are less effective than antacids for symptoms and 
have no evidence for a healing action.5 Since their 
role in maintenance therapy for the prevention of 
recurrence is also contested5 they must be of 
declining usefulness in today's treatment.
3. Antipepsins. These synthetic sulphated muco­
polysaccharides eg. amylopectin are claimed to 
interfere with auto digestion by pepsin. They are 
very expensive and not generally available though 
they may have an effect on recurrence6 , again 
disputed and requiring further evaluation.
4. Mucosal Barrier Fortifying Agents. The first of 
the new generation compounds, this group has 
three contenders. Carbenoxolone is a liquorice 
derivative, whose mode of action is not clear, but 
which may stimulate mucus production. When it 
first appeared in produced very poor results in 
duodenal ulcer (Doll, 1962), though effective 
in gastric ulcers, but it has recently been re­
examined in the belief that effective concentrations 
had previously not been realised in the duodenum 
and now a degree of endoscopically proven healing 
has been shown.5 But it has serious disadvantages 
in terms of side effects producing salt and water 
retention and potassium loss. Conventional diu­
retics worsen the potassium loss and spironolactone 
blocks its therapeutic effect which must limit its 
use in duodenal ulcer.
Deglycyrrhinized liqhorice has not been shown 
to speed healing, but chelated Bismuth has, to a 
minor degree5
5. Histamine H 2 Antagonists. Histamine is 
thought to be an intermediate messenger in the 
acid and pepsin secreting pathway in the gastric 
mucosa both for vagal and gastrin stimulated
secretion. The receptor for this is pharmacologically 
different from that mediating bronchial and 
smooth muscle contraction and is designated 
H2 . The first drug to be developed was 
Burimamide which was shown experimentally on 
dogs to reduce acid secretion. However it lacked 
potency and could only be given parenterally, 
and was replaced by Metiamide which was put on 
trial. The largest published trial was the 
International Multicentre Trial8 which followed 
sixty seven patients with endoscopically 
confirmed duodenal ulcer in a metiamide v. 
placebo randomised controlled trial.
Ulcer healing in six weeks was significantly 
increased compared to placebo (Table 1). It also 
produced a statistically significant reduction in 
antacid consumption and daytime pain, measured 
by a self scoring system.
This difference was greater than has been 
shown for the other groups of ulcer healing drugs.
%  endoscopically proven 
healing at six weeks
Placebo 25
Metiamide 1g/day 62 )
J -  67
Metiamide 1.3g/day 73 )
Table 1_______________________________________
However Metiamide had several side effects, the 
most serious of which was bone marrow 
depression which led to one death. This led to the 
toxic thiourea group being replaced by a cyano- 
guanidine group and the new drug cimetidine was 
released for trial.
The results published so far seem to indicate 
that cimetidine is both effective and free from 
major side effects though of course it will be some 
time before the latter can be stated categorically.
Pouder9 produced complete healing in all of 
a series of ten patients on cimetidine 800 or 
1600mg/day, for six weeks. Heggie10 produced 
healing in seventeen of nineteen patients (90%), on 
400mg t.d.s. Bodemar and Walan11 showed 
ninety per cent healing in a series of forty-four 
patients, as against thirty-six per cent on placebo, 
on a regime of 200 or 300mg q.i.d. They also 
followed acid secretion, antacid consumption and 
self assessed symptoms and found a statistically 
significant reduction in all three. Marginally better 
results were found on the higher dose.
Cimetidine has undoubtably been a great 
breakthrough. These series showed ulcer healing
and symptomatic relief in ninety per cent of 
patients, a far better result than has been achieved 
by other drugs. Antacids failed to heal ulcers faster 
than methyl cellulose, the control chosen for one 
trial.
However, one major problem still remains, 
namely that of recurrence, since the now standard 
six week course does not alter the natural history. 
In the series by Heggie10 seven of his seventeen 
patients with healed ulcers had a recurrence within 
a month of stopping treatment. Trials of 
continuous cimetidine as a prophylactic measure 
on a dose of 400mg/day, taken at night, are now 
under way, but early results indicate that this is 
not fully effective.12
Fortunately cimetidine, being as yet free from 
side effects, may, with long term therapy (for 
life?), offer an answer to recurrence for many 
sufferers, but evaluation of this is based on a few 
trials with small numbers of patients followed for 
relatively short periods, and an answer cannot yet 
be given.
Therefore, the treatment of recurrent or 
persistent ulceration is still surgical. The 
indications, which have not altered for some time, 
are reasonably clear. They are:
a. intractable pain, or recurrence of pain with
frequent loss of work
b. complications — pyloric stenosis, perforation
or bleeding
c. presence for five years or more.
The last is a little more controversial but it has 
been stated than an ulcer present for five years 
in unlikely to heal and that the risk from 
complications of having an ulcer for five years is 
similar to that of an operation.
The present authors of “Bailey and Love" 
suggest that patients should "earn " their 
operation, since unless they have suffered from 
some pain or a complication they may be 
ungrateful if significant symptoms arise from 
surgery. But this may change at least in degree in 
future years if recent developments hold good.
Having decided on surgery the choice is wide 
and a short survey of the alternatives may be 
useful. The aim of operation is to reduce the 
amount of acid bathing the duodenum which can 
be achieved by bypassing it, removing a part of the 
secretory apparatus or by removing the stimulus 
to secretion both neural and endocrine.
The earliest operations were gastrectomies 
with duodenal or jejunal anastomosis. This was 
fairly effective but had numerous side effects and
a high mortality. Sectioning of the vagi at the 
oesophageal hiatus was introduced, thus removing 
both direct and gastrin mediated secretion. 
However the vagi control gastric emptying and 
gastric stasis was produced necessitating a drainage 
procedure either by pyloroplasty (at least four 
methods), gastrojejunostomy or antrectomy which 
also has the virtue of removing the gastrin 
mediated stimulus to secretion.
By the mid sixties many surgeons had become 
dissatisfied with these operations. Many variants 
had been tried but despite long experience few 
good results were obtained and new ways to deal 
with the problem were sought.
With titles like T h e  Surgeon's Dilemma'1 the 
papers of the period set out the problem. Partial 
gastrectomy had the lowest recurrence rate but 
serious side effects and a significant mortality. 
Vagotomy and drainage was safer but had a higher 
recurrence rate and a different though no less 
debilitating set of side effects.
This led to the development of a selective vago­
tomy to overcome of the post vagotomy 
symptoms by leaving intact the hepatic and 
coeliac branches, and, most recently, a highly 
selective vagotomy which leaves the antrum 
innervated as well, allowing ' normal gastric 
emptying so that no drainage procedure is 
necessary.
The reasons for dissatisfaction were not hard 
to see. Table 2 lists the incidence of side effects 
and recurrence found in four of the more popular 
procedures. Five hundred and eight patients were 
followed for five to eight years in the Leeds York  
trials. 13-14 Uncharacteristically this series 
produced only one operative death (in the truncal 
vagotomy and pyloroplasty group) partly due to 
selecting out of high risk patients and partly due 
to the great experience of all the participants.
Similar results were obtained in Glasgow15 and 
in America by the Veterans' administration who 
followed 1357 patients.16 These results showed 
that only major gastric resection carried a higher 
mortality — nearly 2%  as against 0.6% — 0.9%  for 
other operations. With their low mortality they 
pointed towards truncal vagotomy and gastro­
jejunostomy or antrectomy as the best operations 
in experienced hands and called for a halt in the 
drift towards vagotomy and pyloroplasty which 
was steadily growing in popularity due in part to 
its more physiological approach.
Nevertheless this still produces a considerable 
and unacceptable burden of sequelae, even in the 
best hands.
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Vago­ Vago­ Sub­ Vago­
tom y tom y total tom y
and and gastrect and
enter­ antrect omy pyloro
ostomy omy plasty
n=119 n=116 n=107 n=164
Epigastric fullness 40.2 36.3 36.5 37.1
Early dumping 17.9 8.6 21.5 11.9
Late dumping 6.0 4.3 0.9 1.9
Nausea 12.8 17.2 23.4 17.6
Food vom iting 4.3 9.6 5.6 4.4
Bile vom iting 14.5 13.8 13.1 10.1
Heartburn 19.8 15.7 8.4 12.6
Flatulence 17.9 22.8 19.8 20.1
Dysphagia 1.1 0.0 0.0 0.6
Reflux 4.0 7.0 4.3 —
Diarrhoea 26.3 23.2 6.5 21.7
Degree o f
certainty of
recurrence
Proven 3 0 1 11
Suspected 4 2 1 7
Very dubious 3 4 3 5
Total 3-10 0-6 1-5 11-23
Table 2
The first major trial o f selective vagotomy was 
by Kennedy in Belfast who followed one hundred 
patients with truncal vagotomy and drainage or 
selective vagotomy and drainage and produced 
a reduction in post operative diarrhoea from 30% 
to 8%, a statistically significant result ( a rare 
event in most of the surgical papers on duodenal 
ulcer ), with similar results for recurrence and 
other symptoms.
Most attention soon turned however to highly 
selective vagotomy which on a theoretical basis 
offered much by not interfering with gastric 
emptying and by not requiring the alimentary 
tract to be opened. It was first performed as early 
as 1957 by G riffith  and Harkins on an 
experimental basis but they included a drainage 
procedure. Andrup in Copenhagen and Johnston 
in Leeds were the first to perform it without 
drainage. Soon many people were trying it and 
reporting their results which, often, were very 
poor for a number of reasons. But many of these 
bad early results pointed to errors of technique 
and procedure and are worth looking at.
One major early fault in technique was an 
incomplete oesophageal clearance and this was 
illustrated by poor results in a number of studies. 
Kronberg in Copenhagen18 produced excellent 
results for dumping, diarrhoea and epigastric fu ll­
ness but a recurrence rate of 22%, after one year. 
Hellenbeck19 in America managed to reduce their 
incidence of recurrence from 15.4 to 6% (one
from seventeen) by increasing their oesophageal 
skeletonisation from two to seven and a half 
centimetres above the cardia. Similarly, another 
study by Kronberg compared four techniques 
fo r the operation with lower recurrence when the 
oesophagus was adequately cleared, finally 
adopting the technique of Goligher which was 
superior for both recurrence and symptoms. 
Another problem, shown by Sohlaurg21 in Bergen 
passes a comment which is pertinent to most of 
what has been discussed so far, namely that good 
results depend on experience operators. The 
Bergen study included a large number of junior 
operators some of whom had only assisted at one 
such operation before undertaking it themselves. 
Though few of their results could be considered 
good, they steadily worsened with the increasing 
inexperience of the operators. It must be 
remembered that most of the good results both for 
the more established and the more recent 
operations have been obtained by very 
experienced surgeons with a special interest in, and 
performing large numbers of, the particular 
operation and so their results w ill be hard to 
repeat, though this is balanced, in part at least, by 
the fact that the new operation is young and 
should improve with age as has been the case with 
most procedures as further improvements in fine 
technique are developed.
In order to assess the place of highly selective 
vagotomy (HSV) in the modern management of 
duodenal ulcer, we must have the answers to three 
questions:
i Is it  safe?
ii. what are its post operative consequences?
iii. is it  effective?
Its safety is least in doubt. Johnston in Leeds 2
sent a questionnaire to all the surgeons he knew to 
be doing HSV's and received replies covering 5539 
patients. This showed an overall mortality of 
0.31%, compared to  0.8% in 6490 cases of truncal 
vagotomy and drainage, and 1.6% in 1725 cases of 
truncal vagotomy and antrectomy from other 
collected series. The only specific mortality related 
to this operation was from upper gastric necrosis 
which accounted for five deaths (0.09%), and 
prompted Johnston to advocate the reperiton- 
isation of the lesser curvature as well as careful 
preservation of vascalature not sacrificed 
necessarily in the procedure.
Reports of post operative sequelae vary, but 
largely agree that they are significantly less than 
for other procedures.
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Grassin 787 1-6 1.1 0.4 0
Hedenstedt 465 0.5-7 1.0 2.0 0
Liarag 265 3-6 6.0 2.0 0
Goligher* 250 2 1.0 2.0 2.0
Holst-Christeson 160 1-4 9.0 Not severe
Kennedy 112 mean 2.2 6.0 7.0 2.0
Lyndon* 100 5 1.0 — —
Sayers* 84 0.5-4 1.2 1.0 1.0 
Table 3 Taken from Andrup 23 except for
(24-26)
The figures in Table 3 for incidences of 
diarrhoea and dumping compare extremely 
favourably with those in Table 2. The problem of 
poor drainage leading to epigastric fullness and 
gastric stasis was anticipated, but reports vary 
enormously. Goligher puts epigastric fullness at 
29%, Sayers at 8%, but Goligher claimed that all 
but one of his patients could eat a normal meal 
without discomfort. Johnston's mammoth 
collected series put gastric stasis, both early and 
late, at 1.3%, with a reoperation required to 
provide drainage in 0.8% Barium and other studies 
have shown that in general liquids drain a little 
faster than usual and solids a little slower.
The series by Lyndon also showed that, 
although all their patients gave a negative 
Hollander test one week post operation, this was 
rapidly changed to a positive rate of 9 4%  after 
three years. However, the level of peak acid output 
on insulin stimulation was only 10%  of the pre-op 
level, and offered no prognostic indicator for 
recurrence.
The incidence of recurrence with this operation 
in general is still not clear. Since it probably takes 
two to three years for a surgeon to familiarise 
himself with the operation and perfect his tech­
nique before he can reasonably compare it with his 
performance of more established procedures, and 
then takes at least five to ten years of follow up 
before reliable rates of recurrence can be 
established, and since no one has this length of 
experience, it would be foolish to make a final 
judgement on figures now available. Nevertheless 
some inferences can be drawn.
Table 3 also shows recurrence rates for most of 
the large series published to date and these vary
from 1 — 9%. Undoubtably these figures will rise 
with time as the follow up lengthens. The best 
result (1% -at 5 years by Lyndon) compares very 
favourably with any other method but in general 
this has not been widely achieved. We can say 
for certain that it will not prove as effective as 
vagotomy and antrectomy or larger gastric 
resections but that it could equal results for vago­
tomy and gastro-jejunostomy and will probably 
be more effective than vagotomy and pyloroplasty. 
Comparisons with selective vagotomy and drain­
age are few, but four randomised controlled trials 
reported by Andrup 23 suggest ‘ near parity on 
recurrence but a strong advantage for the highly 
selective procedure as regards sequelae, though 
these again suffer from small numbers and a short 
follow up.
Thus, H SV  offers an attractive proposition to 
those favouring minimal intervention in the first 
instance, being very safe and largely free from 
side effects, and who consider acceptable the 
possibility of a slightly higher incidence of re­
currence perhaps necessitating a further operation 
at a later date. Those who consider surety as the 
prime consideration must opt for one of the 
established procedures with vagotomy, preferably 
selective, plus antrectomy offering probably the 
best choice. If it were I on the table, I would want 
a surgeon of the former kind.
Summary
On confirmation of the diagnosis of duodenal 
ulcer medical treatment should be instituted. 
This will consist of bed rest, stopping smoking, a 
minimally altered diet and drug therapy in the 
form of cimetidine 1.3 g/day in divided doses with 
additional antacids as required. This will produce 
healing in about 9 0%  of cases within six weeks. 
Thereafter cimetidine 400 mg/day may be useful 
as prophylaxis. For persistent or recurrent ulcers 
(or for complications, with which I have not dealt 
here) surgical treatment is required. The choice of 
operation will continue to depend on the surgeons 
preference but the new operation of H SV , if it 
maintains or improves its reliability as it develops, 
must continue to grow in popularity, offering as it 
does both greater safety and greatly fewer post 
operative symptoms.
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